• Privacy Policy
  • Contact Us
Search
  • Overview
    • About EOM
    • Relentless Science
    • Our Focus
    • EOM Pipeline
    • Clinical Trials
    • News & Media
    • Investors
      • Overview
      • Why Invest
      • News
      • Events & Presentations
      • Stock Info
        • Stock Quote
        • Stock Chart
        • Historical Stock Quote
        • Investment Calculator
      • Financials
        • SEC Filings
      • Governance
        • Executive Management
        • Board of Directors
        • Governance Documents
      • Resources
        • Investor FAQs
        • Information Request Form
        • Investor Contacts
        • Investor Email Alerts
Skip to main content
Company Logo

Powering Relentless Science™

Company Logo

Powering Relentless Science™

  • Overview
    • About EOM
    • Relentless Science
    • Our Focus
    • EOM Pipeline
    • Clinical Trials
    • News & Media
    • Investors
      • Overview
      • Why Invest
      • News
      • Events & Presentations
      • Stock Info
        • Stock Quote
        • Stock Chart
        • Historical Stock Quote
        • Investment Calculator
      • Financials
        • SEC Filings
      • Governance
        • Executive Management
        • Board of Directors
        • Governance Documents
      • Resources
        • Investor FAQs
        • Information Request Form
        • Investor Contacts
        • Investor Email Alerts

Executive Management

Executive Management

Portrait

Irach Taraporewala, Ph.D., Chief Executive Officer

Dr. Irach Taraporewala, EOM CEO and Director, has multiple accomplishments in drug discovery, development and delivery, formulation, medical devices, radiopharmaceuticals, DNA diagnostics, and regulatory affairs. His R&D contributions span several therapeutic areas, including ophthalmology, cancer, inflammation, immunology, endocrine, CNS, infectious disease, malaria, and cachexia. Dr. Taraporewala also was the founder, CEO, President, and Board member of OHR Pharmaceutical.

Portrait

Eli Goldberger, Chief Operating Officer

Eli Goldberger is EOM’s Founder, Chairman and Chief Operating Officer. Mr. Goldberger is a successful entrepreneur, focusing on advancing innovations in pharmaceuticals, women’s health, and energy.

Portrait

Wayne I. Danson, Chief Financial Officer & Treasurer

Wayne I. Danson, CPA, EOM’s Chief Financial Officer and Treasurer, has over 35 years experience in international and corporate taxation, financial advisory services including investment banking and mergers and acquisitions (M&A), business strategy, corporate finance including tax structuring and planning, turnaround consulting, and entrepreneurship. As a former Partner in large multinational accounting firms and a former Chief Executive Officer and Board Member of one of the largest reverse logistics organizations in the country, his technical and corporate financial abilities have proven to be a successful combination.

Portrait

Shalom Z. Hirschman, M.D., Co-Founder, Chief Scientific Officer & Medical Director

Dr. Shalom Z. Hirschman is the Co-founder, Chief Scientific Officer and Medical Director of EOM Pharmaceuticals and has had a long and illustrious career as an academic physician, research scientist, educator, biotechnology entrepreneur and consultant. A graduate of the Albert Einstein College of Medicine, Dr. Hirschman served as intern and resident in medicine at The Massachusetts General Hospital of the Harvard Medical School followed by years of conducting research in molecular biology at the National Institutes of Health in Bethesda, MD. He joined the world-renowned founding faculty of The Mount Sinai School of Medicine where he was appointed as Director of the Division of Infectious Diseases and Professor of Medicine.

For several years Dr. Hirschman also served as vice-chairman of the Department of Medicine. After three decades, he retired from Mount Sinai and joined Advanced Viral Research Corp. as its chief executive officer, president, and chief scientific officer. There he successfully created a new type of peptide-based drug, built an FDA approved manufacturing facility and brought this drug into clinical trials under INDs with the US FDA. He retired from this position and since has served as consultant to educational institutions, biotechnology companies and biotechnology investment funds. Dr. Hirschman was the founder of Xtramedics, the forerunner company of QuantRx, and currently serves as a member of the board. Dr. Hirschman is one of the three founders of Touro College and the Touro University System. He initiated and negotiated the purchase of New York Medical College by Touro College.

Dr. Hirschman has been a member of many distinguished professional bodies including the American Society for Microbiology, the Biophysical Society, the American Association for the Advancement of Science, the American Society for the Study of Liver Diseases, the American Federation for Clinical Research, The Harvey Society and the American Medical Association. He served as Vice Chairman of the Microbiology Section, NY Academy of Sciences and then as Chairman.

Dr. Hirschman was elected to membership and fellowship in the American College of Physicians, the Infectious Diseases Society of America, the Royal Society of Tropical Medicine and Hygiene, the American Society for Clinical Investigation, the Association of American Physicians, the Society for Experimental Biology and Medicine, the American College of Clinical Pharmacology and the Molecular Medicine Society.

Contact Us

EOM PHARMACEUTICALS
136 Summit Ave., Suite 100
Montvale, NJ 07645

(201) 351-0605
info@eompharma.com


Quick Links

  • SEC Filings
  • Investor FAQs
  • Information Request Form
  • Join the Team

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At EOM Pharmaceuticals, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to EOM Pharmaceuticals to send you the requested Investor Email Alert updates.

* Required

*
Investor Alert Options
*





Unsubscribe

Email Alert Sign Up Confirmation

Company Logo
  • Terms & Conditions
© EOM Pharmaceuticals Holdings, Inc. All rights reserved.
Powered By Q4 Inc. 5.91.0.8 (opens in new window)